Biohaven Pharmaceutical Holding Co Ltd.(BHVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BHVN Biohaven Pharmaceutical Holding Co Ltd.

Closed 08-07 16:00:00 EDT

14.66

+0.24

+1.66%

盘后14.66

+0.000.00%

19:34 EDT

High14.93	Low14.44	Vol1.12M
Open14.77	D1 Closing14.42	Amplitude3.40%
Mkt Cap2.21B	Tradable Cap1.82B	Total Shares150.42M
T/O16.48M	T/O Rate0.90%	Tradable Shares124.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BHVN","market":"US","secType":"STK","nameCN":"Biohaven Pharmaceutical Holding Co Ltd.","latestPrice":14.66,"timestamp":1786132800000,"preClose":14.42,"halted":0,"volume":1121821,"hourTrading":{"tag":"盘后","latestPrice":14.66,"preClose":14.66,"latestTime":"19:34 EDT","volume":50725,"amount":743631.34,"timestamp":1786145647714,"change":0,"changeRate":0,"amplitude":0.002046},"delay":0,"changeRate":0.016643550624133162,"floatShares":124000000,"shares":150417084,"eps":-5.440705,"marketStatus":"Closed","change":0.24,"latestTime":"08-07 16:00:00 EDT","open":14.77,"high":14.93,"low":14.44,"amount":16479446.160647,"amplitude":0.033981,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.440705,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1786348800000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1493870400000,"exchange":"NYSE","adjPreClose":14.42,"preHourTrading":{"tag":"盘前","latestPrice":14.53,"preClose":14.42,"latestTime":"09:21 EDT","volume":410,"amount":5957.3,"timestamp":1786108897716,"change":0.11,"changeRate":0.007628,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":14.66,"preClose":14.66,"latestTime":"19:34 EDT","volume":50725,"amount":743631.34,"timestamp":1786145647714,"change":0,"changeRate":0,"amplitude":0.002046},"volumeRatio":0.641121,"impliedVol":0.8782,"impliedVolPercentile":0.1912},"requestUrl":"/m/hq/s/BHVN/wiki","defaultTab":"wiki","newsList":[{"id":"2657626374","title":"Biohaven Appoints John Yetimoglu to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2657626374","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657626374?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:12","pubTimestamp":1786133536,"startTime":"0","endTime":"0","summary":"Biohaven appoints John Yetimoglu to boardBiohaven appointed John Yetimoglu to its board, effective Aug. 6, 2026.Yetimoglu will serve in the director class up for election at the 2027 annual shareholde","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL5xHQb2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","BK4139","BHVN","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655524433","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2655524433","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655524433?lang=en_us&edition=fundamental","pubTime":"2026-07-31 18:00","pubTimestamp":1785492000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.Company                                   Symbol     Quarter  Mean  Report Time. ·Arbor Rlty Tr.                                    2Q       .05    8:30 AM. ·Church & Dwight                                   2Q       .90    6:55 AM. ·Eaton Corp. Plc                                   2Q      3.07    6:30 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMEA","BRK.A","ADTN","ALSN","MOG.B","BRK.B","CSR","ARES","CBT","CLPT","CHD","AVA","CLAR","ALDX","ABR","CVGI","BTSG","ABBV","CRGY","ARE","ADUS","CRI","BCBP","CGEN","BSM","AN","ADEA","CL","CRD.B","CLX","AESI","AU","CRD.A","BEN","CCJ","CVX","D","CTOS","BLDP","ALG","CNH","AMRC","ANDE","BHVN","BEP","AEIS","BWXT","BCC","CSWC","BLZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654277530","title":"How Biohaven’s (BHVN) Trade Secret Verdict Shapes Its Intellectual Property Defense Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2654277530","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654277530?lang=en_us&edition=fundamental","pubTime":"2026-07-28 10:17","pubTimestamp":1785205053,"startTime":"0","endTime":"0","summary":"Earlier this week, Biohaven disclosed that a federal jury awarded the company US$1,000,000 in damages in a trade secret lawsuit against Avilar Therapeutics and RA Capital Management.\nThe verdict underscores the legal weight behind Biohaven’s efforts to safeguard its intellectual property, a core asset for any research‑driven biopharmaceutical business.\nNext, we’ll examine how this courtroom win on intellectual property protection shapes Biohaven’s broader investment narrative over the coming...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/how-biohavens-bhvn-trade-secret-verdict-shapes-its-intellect","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/how-biohavens-bhvn-trade-secret-verdict-shapes-its-intellect","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["JJJ.SI","SRU.SI","CLR.SI","SRT.SI","LU1093756168.USD","BK4139","CFA.SI","GLS.SI","LU1093756325.SGD","BHVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654172210","title":"Biohaven Awarded $1 Million Over Alleged Trade Secret Violations by Avilar Therapeutics, RA Capital Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2654172210","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654172210?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:10","pubTimestamp":1785154225,"startTime":"0","endTime":"0","summary":"Biohaven  said Monday that a federal jury has awarded it $1 million in damages over an alleged trade secret misappropriation by Avilar Therapeutics and RA Capital Management.The jury found that after Yale shared confidential technical information about its MODA targeted protein degradation platform with RA Capital related to a possible deal, RA Capital shared the technology with Avilar Therapeutics to develop a rival platform, the company said.Biohaven said it licensed the MODA platform from Yale, which was developed by Yale professor David Spiegel, to develop and commercialize the technology.Yale received $2 million for RA Capital's breach of contract, and $1 million for trade secret misappropriation.\"This verdict confirms what we have said since we filed this case: RA Capital and Avilar improperly used confidential information to advance a competing company, and the jury agreed that they did so willfully and maliciously,\" Biohaven Chief Executive Vlad Coric said in a statement.Avilar","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4007","LU1093756325.SGD","LENZ","RA","LU1093756168.USD","BHVN","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654014545","title":"Biohaven, Yale Win USD 4 Million Jury Verdict over MODA Trade Secret Theft","url":"https://stock-news.laohu8.com/highlight/detail?id=2654014545","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654014545?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:03","pubTimestamp":1785150226,"startTime":"0","endTime":"0","summary":"Biohaven, Yale win USD 4 million jury verdict over MODA trade secret theftBiohaven won a U.S. federal jury verdict in Delaware against Avilar Therapeutics, RA Capital over alleged misappropriation of ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nNDLLJxf3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BHVN","BK4139","LU1093756168.USD","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652218511","title":"Biohaven reports new data on BHV-1530","url":"https://stock-news.laohu8.com/highlight/detail?id=2652218511","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652218511?lang=en_us&edition=fundamental","pubTime":"2026-07-20 19:35","pubTimestamp":1784547341,"startTime":"0","endTime":"0","summary":"Biohaven (BHVN) announced that new data on BHV-1530, its FGFR3-directed antibody-drug conjugate, or ADC, using a novel topoisomerase I, or TopoIx, ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biohaven-reports-new-data-on-bhv-1530-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biohaven-reports-new-data-on-bhv-1530-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BHVN","BHV","LU1093756168.USD","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652183622","title":"Biohaven enters into clinical supply agreement with Regeneron","url":"https://stock-news.laohu8.com/highlight/detail?id=2652183622","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652183622?lang=en_us&edition=fundamental","pubTime":"2026-07-20 19:35","pubTimestamp":1784547336,"startTime":"0","endTime":"0","summary":"Biohaven (BHVN) has entered into a clinical supply agreement with Regeneron Pharmaceuticals (REGN) to evaluate the combination of BHV-1530 and cemi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biohaven-enters-into-clinical-supply-agreement-with-regeneron-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biohaven-enters-into-clinical-supply-agreement-with-regeneron-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2106854487.HKD","BBH","LU1974910355.USD","LU2089984988.USD","IBBQ","LU2362540622.SGD","LU2362541273.HKD","LU0889565916.HKD","LU0320765992.SGD","LU0823416689.USD","LU2237438978.USD","LU0109394709.USD","REGN","IBB","BK4139","LU0114720955.EUR","LU2468319806.SGD","LU0053666078.USD","BHVN","LU1917777945.USD","LU2023250504.SGD","LU0058720904.USD","LU2362541513.USD","BK4588","LU0823434583.USD","LU1093756168.USD","BK4585","LU0823434740.USD","LU0882574055.USD","LU0289739699.SGD","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652029008","title":"Biohaven Signs Regeneron Supply Deal to Test Bhv-1530 with Libtayo","url":"https://stock-news.laohu8.com/highlight/detail?id=2652029008","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652029008?lang=en_us&edition=fundamental","pubTime":"2026-07-20 19:31","pubTimestamp":1784547070,"startTime":"0","endTime":"0","summary":"Biohaven signs Regeneron supply deal to test BHV-1530 with LibtayoBiohaven entered a clinical supply agreement with Regeneron to test FGFR3-targeted ADC BHV-1530 with cemiplimab (Libtayo) in solid tum","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nNDL6byGmB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","BK4588","LU1917777945.USD","IBB","LU0823434740.USD","LU0289739699.SGD","REGN","LU2468319806.SGD","LU0058720904.USD","BBH","LU0889565916.HKD","LU2362541513.USD","IBBQ","LU2362541273.HKD","LU0053666078.USD","LU0109394709.USD","LU2023250504.SGD","LU2106854487.HKD","LU0882574055.USD","BK4139","LU0114720955.EUR","LU1093756168.USD","LU2237438978.USD","BK4585","LU0823434583.USD","LU1974910355.USD","LU0823416689.USD","BHVN","LU2362540622.SGD","LU2089984988.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652290745","title":"Biohaven to Present New Clinical Data at Esmo Congress on Bhv-1530, a Novel Fgfr3-directed ADC with a Proprietary Topoisomerase I (topoix) Payload","url":"https://stock-news.laohu8.com/highlight/detail?id=2652290745","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652290745?lang=en_us&edition=fundamental","pubTime":"2026-07-20 19:30","pubTimestamp":1784547002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nTUA31J1TV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1093756168.USD","BK4139","LU1093756325.SGD","BHVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652233697","title":"Biohaven Files Form 3 for Chief Legal Officer Warren Karl Volles","url":"https://stock-news.laohu8.com/highlight/detail?id=2652233697","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652233697?lang=en_us&edition=fundamental","pubTime":"2026-07-18 06:01","pubTimestamp":1784325664,"startTime":"0","endTime":"0","summary":"Biohaven files Form 3 for Chief Legal Officer Warren Karl VollesBiohaven Chief Legal Officer Warren Karl Volles reported 248,212 common shares, with stock options covering 731,000 shares in an initial","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nNDL7r0Qs1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BHVN","LU1093756325.SGD","BK4139","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650972712","title":"Biohaven Chief Scientific Officer Bruce Car to Transition to Chief Innovation Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2650972712","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650972712?lang=en_us&edition=fundamental","pubTime":"2026-07-10 05:27","pubTimestamp":1783632476,"startTime":"0","endTime":"0","summary":"Biohaven (BHVN) said late Thursday that Chief Scientific Officer Bruce Car will retire from the role and transition to the newly created position of chief innovation officer, effective July 13.Car wil","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1093756168.USD","BHVN","LU1093756325.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650972271","title":"Biohaven’s Bruce Car retires as chief scientific officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2650972271","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650972271?lang=en_us&edition=fundamental","pubTime":"2026-07-10 05:05","pubTimestamp":1783631116,"startTime":"0","endTime":"0","summary":"Biohaven (BHVN) announced scientific leadership role transitions designed to accelerate drug innovation and external collaborations. David Pirman, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biohavens-bruce-car-retires-as-chief-scientific-officer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biohavens-bruce-car-retires-as-chief-scientific-officer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU1093756325.SGD","BHVN","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650972693","title":"Biohaven Promotes David Pirman to EVP, Head of Discovery","url":"https://stock-news.laohu8.com/highlight/detail?id=2650972693","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650972693?lang=en_us&edition=fundamental","pubTime":"2026-07-10 05:00","pubTimestamp":1783630824,"startTime":"0","endTime":"0","summary":"Biohaven promotes David Pirman to EVP, head of discoveryBiohaven promoted David Pirman to executive vice president, head of discovery to run internal drug discovery and oversee research programs.Bruce","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nNDL3ySP0F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BHVN","LU1093756168.USD","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650697263","title":"Press Release: Biohaven Announces Scientific Leadership Transitions","url":"https://stock-news.laohu8.com/highlight/detail?id=2650697263","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650697263?lang=en_us&edition=fundamental","pubTime":"2026-07-10 05:00","pubTimestamp":1783630800,"startTime":"0","endTime":"0","summary":"-- David Pirman, Ph.D. promoted to Executive Vice President and Head of. -- Bruce Car, Ph.D. transitioning from Chief Scientific Officer to new role. as Chief Innovation Officer focusing on external collaborations. -- Warren Volles, General Counsel and Chief Legal Officer, also designated","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","BK4139","LU1093756168.USD","BHVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648545350","title":"Analysts’ Top Healthcare Picks: Heart Test Laboratories, Inc. (HSCS), Biohaven Ltd. (BHVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2648545350","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648545350?lang=en_us&edition=fundamental","pubTime":"2026-07-01 21:00","pubTimestamp":1782910821,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Heart Test Laboratories, Inc. (HSCS) and Biohaven Lt...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-heart-test-laboratories-inc-hscs-biohaven-ltd-bhvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-heart-test-laboratories-inc-hscs-biohaven-ltd-bhvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","HCSG","LU0029874061.USD","BK4581","LU1093756325.SGD","XLV","BK4588","BK4139","XBI","BK4585","BHVN","HSCS","BK4082","LABU","LU1093756168.USD","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647558226","title":"Biohaven announces completion of enrollment in RISE3 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2647558226","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647558226?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:35","pubTimestamp":1782819353,"startTime":"0","endTime":"0","summary":"Biohaven (BHVN) announced the completion of enrollment in RISE3, a pivotal Phase 2/3 randomized, double-blind, placebo-controlled studies evaluatin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biohaven-announces-completion-of-enrollment-in-rise3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biohaven-announces-completion-of-enrollment-in-rise3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1093756325.SGD","BHVN","BK4139","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647939558","title":"Biohaven - Completes Enrollment in Rise3 Pivotal Phase 2/3 Focal Epilepsy Study with Opakalim","url":"https://stock-news.laohu8.com/highlight/detail?id=2647939558","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647939558?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:31","pubTimestamp":1782819089,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nFWN4320AE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1093756325.SGD","BK4139","BHVN","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647558607","title":"Biohaven - Top-line Results from Rise3 Study Expected in Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2647558607","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647558607?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:31","pubTimestamp":1782819089,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nFWN4320AE:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1093756168.USD","BHVN","LU1093756325.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647558670","title":"Biohaven Completes Enrollment in RISE3 Pivotal Opakalim Focal Epilepsy Trial, Data Due 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2647558670","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647558670?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:30","pubTimestamp":1782819026,"startTime":"0","endTime":"0","summary":"Biohaven completes enrollment in RISE3 pivotal opakalim focal epilepsy trial, data due 2H 2026Biohaven completed enrollment in RISE3, a pivotal Phase 2/3 trial of opakalim as add-on therapy for refrac","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL2MrJk8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BHVN","LU1093756168.USD","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647830984","title":"Biohaven Shares Down as Phase 3 Trial Concerns Trigger Downgrade at Bofa","url":"https://stock-news.laohu8.com/highlight/detail?id=2647830984","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647830984?lang=en_us&edition=fundamental","pubTime":"2026-06-30 01:49","pubTimestamp":1782755340,"startTime":"0","endTime":"0","summary":"Shares of Biohaven retreated after they were downgraded by analysts at Bank of America on concerns about the upcoming readout from a Phase 3 trial for the company's epilepsy drug, known as Opakalim.The stock was down 6.3% at $14.84 in Monday afternoon trading. Shares have risen 31% this year.Even under the best case scenario, the analysts wrote, data for Biohaven's drug is likely to be undifferentiated when compared to Xenon Pharmaceuticals' investigative epilepsy treatment, known as azetukalnar.  Undifferentiated data would cast doubt on the consensus view that Biohaven could reach $1 billion in peak sales for the drug, they added.Biohaven's drug is identified Opakalim on the company's web site.\"Uncompelling Kv data could pressure shares given the company's cash runway concerns and the other sole 2026 catalyst  carries low derisking value,\" the analysts added.They downgraded the stock to underperform from neutral and cut its price target to $11 from $12.Write to Elias Schisgall at eli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","BK4139","BHVN","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biohaven.com","stockEarnings":[{"period":"1week","weight":0.0434},{"period":"1month","weight":-0.0727},{"period":"3month","weight":0.4625},{"period":"6month","weight":0.2431},{"period":"1year","weight":-0.0425},{"period":"ytd","weight":0.2772}],"compareEarnings":[{"period":"1week","weight":0.0362},{"period":"1month","weight":0.0279},{"period":"3month","weight":0.0419},{"period":"6month","weight":0.1129},{"period":"1year","weight":0.2146},{"period":"ytd","weight":0.1271}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.071849},{"month":2,"riseRate":0.222222,"avgChangeRate":-0.026101},{"month":3,"riseRate":0.222222,"avgChangeRate":-0.120539},{"month":4,"riseRate":0.555556,"avgChangeRate":0.027819},{"month":5,"riseRate":0.666667,"avgChangeRate":0.144578},{"month":6,"riseRate":0.6,"avgChangeRate":0.085557},{"month":7,"riseRate":0.5,"avgChangeRate":0.000445},{"month":8,"riseRate":0.7,"avgChangeRate":0.045843},{"month":9,"riseRate":0.777778,"avgChangeRate":0.09598},{"month":10,"riseRate":0.555556,"avgChangeRate":-0.072057},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.042561},{"month":12,"riseRate":0.555556,"avgChangeRate":0.054983}],"exchange":"NYSE","name":"Biohaven Pharmaceutical Holding Co Ltd.","nameEN":"Biohaven Pharmaceutical Holding Co Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biohaven Pharmaceutical Holding Co Ltd.(BHVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biohaven Pharmaceutical Holding Co Ltd.(BHVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biohaven Pharmaceutical Holding Co Ltd.,BHVN,Biohaven Pharmaceutical Holding Co Ltd.股票,Biohaven Pharmaceutical Holding Co Ltd.股票老虎,Biohaven Pharmaceutical Holding Co Ltd.股票老虎国际,Biohaven Pharmaceutical Holding Co Ltd.行情,Biohaven Pharmaceutical Holding Co Ltd.股票行情,Biohaven Pharmaceutical Holding Co Ltd.股价,Biohaven Pharmaceutical Holding Co Ltd.股市,Biohaven Pharmaceutical Holding Co Ltd.股票价格,Biohaven Pharmaceutical Holding Co Ltd.股票交易,Biohaven Pharmaceutical Holding Co Ltd.股票购买,Biohaven Pharmaceutical Holding Co Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biohaven Pharmaceutical Holding Co Ltd.(BHVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biohaven Pharmaceutical Holding Co Ltd.(BHVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction